FocusCancer

New twists in the AXL(e) of tumor progression

Sci. Signal.  04 Oct 2016:
Vol. 9, Issue 448, pp. fs14
DOI: 10.1126/scisignal.aai7619

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients.

View Full Text

Related Content